Статья
Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Междисциплинарный консенсус
Разработан экспертами Российского научного медицинского общества терапевтов (РНМОТ), Российского общества профилактики неинфекционных заболеваний (РОПНИЗ), Национальной ассоциации нефрологов (НАН), Профессиональной ассоциации нефрологов (ПАН), Российского кардиологического общества (РКО), Российского медицинского общества по артериальной гипертонии (РМОАГ), Общества специалистов по сердечной недостаточности (ОССН), Национального общества по изучению атеросклероза (НОА), Российской ассоциации эндокринологов (РАЭ), Российской ассоциации геронтологов и гериатров (РАГГ).Согласованное мнение экспертов составлено на основании соответствующих разделов национальных и международных клинических рекомендаций по хронической болезни почек, профилактике и лечению атеросклероза, артериальной гипертонии, сахарного диабета и сердечной недостаточности.
1. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и НОНР. Кардиоваскулярная терапия и профилактика. 2008;7(6 S3):1-20. EDN WATIVJ.
2. Моисеев В. С., Мухин Н. А., Смирнов А. В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;(8):7-37. doi:10.15829/1560-4071-2014-8-7-37.
3. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD Chronic Kidney Disease Collaboration. Lancet. 2020;395:709-33. doi:10.1016/S0140-6736(20)30045-3.
4. Francis A, Harhay MN, Ong ACM, et al.; American Society of Nephrology; European Renal Association; International Society of Nephrology. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;3. doi:10.1038/s41581-024-00820-6.
5. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):SI-266.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018.
7. Ткачева О. Н., Котовская Ю. В., Бобкова И. Н. и др. Хроническая болезнь почек у пациентов пожилого и старческого возраста. Согласованное мнение экспертов Российской ассоциации геронтологов и гериатров, Научного общества нефрологов России и Евразийской ассоциации терапевтов. Российский журнал гериатрической медицины. 2024;(1):6-20. doi:10.37586/2686-8636-1-2024-6-20.
8. Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication — worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803-5.
9. Bello AK, Okpechi IG, Levin A, et al.; and the ISN-GKHA Group. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12:e382-95.
10. Sozio SM, Pivert KA, Caskey FJ, Levin A. The state of the global nephrology workforce: a joint ASN-ERA-EDTA-ISN investigation. Kidney International. 2021;100:995-1000. doi:10.1016/j.kint.2021.07.029.
11. Ortiz A, Wanner C, Gansevoort R, ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. European Journal of Preventive Cardiology. 2022; 29:2211-5. doi:10.1093/eurjpc/zwac186.
12. Смирнов А. В., Каюков И. Г., Есаян A. M. и др. Превентивный подход в современной нефрологии. Нефрология. 2004;8(3):7-14. doi:10.24884/1561-6274-2004-8-3-7-14.
13. Смирнов А. В., Добронравов В. А., Каюков И. Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология. 2006;10(1):7-13.
14. Ощепкова Е. В., Долгушева Ю. А., Жернакова Ю. В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19-24.
15. Бойцов С. А., Драпкина О. М., Шляхто Е. В. и др. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021;20(5):3007. doi:10.15829/1728-8800-2021-3007.
16. Кобалава Ж. Д., Виллевальде С. В., Боровкова Н. Ю. и др. От имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017;57(10):39-44. doi:10.18087/cardio.2017.10.10041.
17. Кобалава Ж. Д., Виллевальде С. В., Багманова Н. Х. и др. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией в зависимости от наличия сахарного диабета: результаты эпидемиологического исследования ХРОНОГРАФ. Российский кардиологический журнал. 2018;(2):91-101. doi:10.15829/1560-4071-2018-2-91-101.
18. Дедов И. И., Шестакова М. В., Викулова О. К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010 — 2022 гг. Сахарный диабет. 2023;26(2):104-23. doi:10.14341/DM13035.
19. Шляхто Е. В., Беленков Ю. Н., Бойцов С. А. и др. Результаты промежуточного анализа проспективного наблюдательного многоцентрового регистрового исследования пациентов с хронической сердечной недостаточностью в Российской Федерации "ПРИОРИТЕТ-ХСН": исходные характеристики и лечение первых включенных пациентов. Российский кардиологический журнал. 2023;28(10):5593. doi:10.15829/1560-4071-2023-5593.
20. Андрусев А. М., Томилина Н. А., Перегудова Н. Г., Шинкарев М. Б. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Отчет по данным общероссийского регистра заместительной почечной терапии российского диализного общества. Нефрология и диализ. 2020;22(S1):1-71.
21. Prikhodina L, Komissarov K, Bulanov N, et al.; Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Newly Independent States and Russia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney Int Suppl (2011). 2024;13(1):71-82. doi:10.1016/j.kisu.2024.01.005.
22. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1): A6-A7. doi:10.1053/j.ajkd.2019.09.003.
23. McCullough KP, Morgenstern H, Saran R, et al. Projecting ESRD Incidence and Prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30:127-35. doi:10.1681/ASN.2018050531.
24. Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81.
25. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIG0 Controversies Conference report. Kidney int. 2011;80(l):17-28. doi:10.1038/ki.2010.483.
26. Foley R, Murray A, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am SocNephrol. 2005;16:489-95.
27. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns — NHANES 2007-2012. BMJ Open Diabetes Research and Care. 2016;4:e000154. doi:10.1136/bmjdrc-2015-000154.
28. Visseren FLJ, Mach F, Smulders YM, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021;42(34):3227-337.
29. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
30. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S):S1-S115.
31. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-83. doi:10.2337/dc14-1296.
32. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. doi:10.1016/S0140-6736(12)61350-6.
33. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, О. Ю. Сухаревой. 12-й выпуск. М.; 2025. c. 248.
34. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.
35. Böhm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens. 2007;25(11):2317-24.
36. Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939.
37. Lopez R, Copeland T, McCulloch C, et al. Additive effects of intensive BP control and ACE inhibition on suppression of proteinuria in patients with CKD. JHumHypertens. 2023;37(5):419-21. doi:10.1038/s41371-023-00823-z.
38. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi:10.15829/ 1560-4071-2024-6117.
39. Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.
40. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
41. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am CollCardiol. 2003;41(1):47-55.
42. Matsushita K, Ballew SH, Wang AY, et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696-707. doi:10.1038/s41581-022-00616-6.
43. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-25. doi:10.1016/S2213-8587(15)00040-6.
44. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J. 2008;155:725-31.
45. Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004; 25(22):1998-2005.
46. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.
47. Panchal HB, Zheng S, Devani K, et al. Impact of chronic kidney disease on revascularization and outcomes in patients with ST-elevation myocardial infarction. Am J Cardiol. 2021;150:15-23. doi:10.1016/j.amjcard.2021.03.057.
48. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89:1003-8.
49. Junho CVC, Frisch J, Soppert J, et al. Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology. Clin Kidney J. 2023;16(11):1786-803. doi:10.1093/ckj/sfad085.
50. Grams ME, Coresh J, Matsushita K, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes. An Individual-Participant Data Meta-Analysis. JAMA. 2023;330(13):1266-77. doi:10.1001/jama.2023.17002.
51. Collins AJ, Vassalotti JA, Wang C, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. Am J Kidney Dis. 2009;53 (Suppl 3):71-7.
52. Herzog C. Kidney disease in cardiology. Nephrol Dial Transplant. 2008;23(8):42-6.
53. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am SocNephrol. 2002;13(5):1338-49.
54. Nitsch D, Grams M, Sang Y, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324. doi:10.1136/bmj.f324.
55. Claudel SE, Waikar SS, Schmidt IM, et al. The relationship between low levels of albuminuria and mortality among adults without major cardiovascular risk factors. Eur J Prev Cardiol. 2024; 31(17):2046-55. doi:10.1093/eurjpc/zwae189.
56. Claudel SE, Verma A. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation. 2025;151(10):716-32. doi:10.1161/CIRCULATIONAHA.124.071079.
57. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44(37): 3627-39. doi:10.1093/eurheartj/ehad195.
58. Marcos MC, Espriella R, Ordás JG, et al. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry. Revista Española de Cardiología (English Edition). 2024;77,1:50-9.
59. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am SocNephrol. 2007;18:1307-15. doi:10.1681/ASN.2006101159.
60. Parmar SS, Muthuppalaniappan V, Debasish B. Gaps in Modern Heart Failure and Chronic Kidney Disease Research, European Cardiology Review. 2023;18:e51. doi:10.15420/ecr.2022.64.
61. Ronco C, McCullough P, Anker S, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31:703-11.
62. Zhang J, Hu Z, Tan Y, Ye J. Causal relationship from heart failure to kidney function and CKD: A bidirectional two-sample mendelian randomization study. PLoS ONE. 2023;18(12):e0295532. doi:10.1371/journal.pone.0295532.
63. Zoccali C, Mallamaci F, Adamczak M, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11): 2017-32. doi:10.1093/cvr/cvad083.
64. Löfman I, Szummer K, Evans M, et al. Incidence of, Associations With and Prognostic Impact of Worsening Renal Function in Heart Failure With Different Ejection Fraction Categories. Am. J. Cardiol. 2019;124:1575-83.
65. Heywood JT, Fonarow GC, Costanzo MR, et al.; Committee ASA Investigators (2007). High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422-30. doi:10.1016/j.cardfail.2007.03.011.
66. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-8. doi:10.1161/CIRCULATIONAHA.105.580506.
67. Patel RB, Fonarow GC, Greene SJ, et al. Kidney function and outcomes in patients hospitalized with heart failure. JAmCollCardiol. 2021;78:330-43.
68. Межонов Е. М., Рейтблат О. М., Вялкина Ю. А. и др. Хроническая болезнь почек и хроническая сердечная недостаточность: влияние на прогноз и выбор патогенетической терапии. Терапевтический архив. 2024;96(7):666-74. doi:10.26442/00403660.2024.07.202781.
69. Wilson P, D’Agostino Rb, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-72.
70. Кобалава Ж. Д., Моисеев В. С. Концепция кардиоренальных и метаболических соотношений в современной профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2008;7(4):4-7.
71. Мухин Н. А., Балкаров И. М., Моисеев В. С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевтический архив. 2004;(9):5-10.
72. Кобалава Ж. Д., Котовская Ю. В., Толкачева В. В., Мильто А. С. Мочевая кислота — ключевой компонент кардиренометаболического континуума. Кардиоваскулярная терапия и профилактика. 2008;7(4):95-100.
73. Desai RJ, Franklin JM, Spoendlin-Allen J, et al. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One. 2018;13(2):e0193622. Published online 2018. doi:10.1371/journal.pone.0193622.
74. Despres J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8(suppl. B):4-12.
75. Pommer W. Preventive Nephrology: The Role of Obesity in Different Stages of Chronic Kidney Disease. Kidney Dis. 2018;4:199-204. doi:10.1159/000490247.
76. Ndumele CE, Rangaswami J, Chow SL, et al.; on behalf of the American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606-35. doi:10.1161/CIR.0000000000001184.
77. Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. CurrProblCardiol. 2024;49(2):102344. doi:10.1016/j.cpcardiol.2023.102344.
78. Roghi A, Savonitto S, Cavallini C, et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med. 2008;9:375-81.
79. Bagshaw SM, Lapinsky S, Dial S, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009;35:871-81.
80. Latchamsetty R, Fang J, Kline-Rogers E, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol. 2007;99(7):939-42.
81. Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am SocNephrol. 2006;17:2886-91.
82. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002 8:136-41.
83. Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006;27:1216-22.
84. Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes in critical care. ContribNephrol. 2010; Basel, Karger, 2010, vol 165, 366 p.
85. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012;2:1-138.
86. Tangri N, Grams ME, Levey AS, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis JAMA. 2016; 315(2):1-11. doi:10.1001/jama.2015.18202.
87. Vondenhoff S, Schunk SJ, Noels H. Increased cardiovascular risk in patients with chronic kidney disease. Herz. 2024;49:95-104.
88. Ткачева О. Н., Котовская Ю. В., Рунихина Н. К. и др. Клинические рекомендации "Старческая астения". Российский журнал гериатрической медицины. 2025;(1):6-48. doi:10.37586/2686-8636-1-2025-6-48.
89. Ku E, Sarnak MJ, Toto R, et al. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. J Am Heart Assoc. 2019;8(16):e012749. doi:10.1161/JAHA.119.012749.
90. Wright Jr JT, Bakris G, Greene T, et al. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial. JAMA. 2002;288(19):2421-31. doi:10.1001/jama.288.19.2421.
91. Ruggenenti P, Perna A, Loriga G, et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-46. doi:10.1016/S0140-6736(05)71082-5.
92. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am SocNephrol. 2009;20:883-92.
93. McEvoy JW, McCarthy CP, Bruno RM, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38):3912-4018. doi:10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025;46(14):1300. doi:10.1093/eurheartj/ehaf031.
94. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. doi:10.1016/S2213-8587(20)30369-7.
95. Zelniker TA, Wiviott SD, RazfI, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-9.
96. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canaglifozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306.
97. Giugliano D, De Nicola L, Maiorino MI, et al. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovasc Diabetol. (2020);19:35. doi:10.1186/s12933-020-01010-x.
98. Bhatt DL, Szarek M, Pitt B, et al. Sotaglifozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2): 117-28. doi:10.1056/NEJMoa2030183.
99. Docherty KF, Jhund PS, Anand I, et al. Effect of dapaglifozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142:1623-32.
100. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empaglifozin in heart failure. N Engl J Med. 2020;383: 1413-24.
101. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; for the DAPA-CKD Trial Committees and Investigators. Dapaglifozin in patients with chronic kidney disease. N Engl J Med. 2020; 383:1436-46.
102. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023; 388(2):117-27. doi:10.1056/NEJMoa2204233.
103. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose cotransporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365):1788-801. doi:10.1016/S0140-6736(22)02074-8.
104. Tsai WC, Hsu SP, Chiu YL, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022;12(10):e060655. doi:10.1136/bmjopen-2021-060655.
105. Pitt B, Filippatos G, Agarwal R, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-63.
106. Agarwal R, Filippatos G, Pitt B, et al.; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84.
107. Rossing P, Anker SD, Filippatos G, et al.; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022;45:2991-8. doi:10.2337/dc22-0294.
108. Agarwal R, Fouque D. The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes. Nephrol Dial Transplant. 2023; 38(2):253-7. doi:10.1093/ndt/gfac331.
109. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:1269-324.
110. Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41. doi:10.1053/j.ajkd.2015. 10.011.
111. Huang RS, Cheng YM, Zeng XX, et al. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chin Med J (Engl). 2016;129(5):562-9. doi:10.4103/0366-6999.176987.
112. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
113. Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results From ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7(18):e9326. doi:10.1161/JAHA.118.009326.
114. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am SocNephrol. 2012;7:1234-41.
115. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert OpinPharmacother. 2015;16:2205-15.
116. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181-92.
117. Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016; 4:829-39.
118. Barylski M, Nikfar S, Mikhailidis DP, et al.; Lipid and Blood Pressure Meta Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy — a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35-44.
119. Charytan DM, Sabatine MS, Pedersen TR, et al.; FOURIER Steering Committee and Investigators. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am CollCardiol. 2019;73:2961-70.
120. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. KidneyInt. 2014;85:1303-9.
121. Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. EurHeart J. 2020;41:111-88.
122. de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90. doi:10.2337/dci22-0027.
123. Giugliano D, Bellastella G, Longo M, et al. Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes Obes Metab. 2020;22:1397-405.
124. Huang HD, Alam M, Hamzeh I, et al. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol. 2013;168:3741-6. doi:10.1016/j.ijcard.2013.06.013.
125. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120:851-8. doi:10.1161/circulationaha.108.83816.
126. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268:40-9. doi:10.1111/j.1365-2796.2009.02204.x.
127. Аверков О. В., Арутюнян Г. К., Дупляков Д. В. и др. Острый инфаркт миокарда без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(5):6319. doi:10.15829/1560-4071-2025-6319. EDN CXJUIB.
128. Аверков О. В., Арутюнян Г. К., Дупляков Д. В. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(3):6306. doi:10.15829/1560-4071-2025-6306. EDN IVJCUK.
129. Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191. Erratum in: Eur Heart J. 2024; 45(13):1145. doi:10.1093/eurheartj/ehad870.
130. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. KidneyMed. 2020;2:85-93. doi:10.1016/j.xkme.2020.01.001.
131. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. J Am Coll Card Cardiovasc Interv. 2014;7(1):1-9. doi:10.1016/j.jcin.2013.06.016.
132. Watabe H, Sato A, Hoshi T, et al. Association of contrastinduced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol. 2014;174(1):57-63.
133. Белопухов В. М., Якупов И. Ф., Айнутдинова И. А., Иванова А. Ю. Нарушения функции почек у больных с инфарктом миокарда и чрескожными коронарными вмешательствами в до– и послеоперационном периоде. Медицинский альманах. 2013;4(28):55-6.
134. Stacul F, Adam A, Becker CR, et al. Strategies to reduсe the risk of contrast — induced nephropathy. Am. J. Cardiol. 2006;98:59-77.
135. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int. Supplement. 2006;100:16-9.
136. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038-46.
137. Кunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephronpathy: a meta-analysis of published clinical trials. Eur. J. Radiol. 2011;79:48-55.
138. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction ofcontrast-induced nephropathy after percutaneous coronary intervention: developmentand initial validation. J Am Coll Cardiol. 2004;44(7):1393-9.
139. Боровкова Н. Ю., Ильина А. С., Спасский А. А. и др. Цитопротективная терапия при почечном повреждении у больных острым инфарктом миокарда с подъемом сегмента ST. Кардиология и сердечно-сосудистая хирургия, 2017:1. doi:10.17116/kardio201710138-41.
140. Сагынбаева Г. А., Калиев Р. Р. Эффективность N-ацетилцистеина и мексидола в профилактике контраст-индуцированной нефропатии у больных коронарной болезнью сердца. Наука, новые технологии и инновации Кыргызстана, 2020:8. doi:10.26104/NNTIK.2019.45.557.
141. Mullens W, Martens P, Testani JM, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(4):603-19. doi:10.1002/ejhf.2471.
142. Guaricci AI, Sturdà F, Russo R, et al. Assessment and management of heart failure in patients with chronic kidney disease. Heart Fail Rev. 2023. doi:10.1007/s10741-023-10346-x.
143. Галявич А. С., Терещенко С. Н., Ускач Т. М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. doi:10.15829/1560-4071-2024-6162. EDN WKIDLJ.
144. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726. doi:10.1093/eurheartj/ehab368.
145. Vukadinović D, Lavall D, Vukadinović AN, et al. True rate of mineralocorticoid receptor antagonists related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J. 2017; 188:99-108. doi:10.1016/j.ahj.2017.03.011.
146. Wetmore JB, Yan H, Horne L, et al. Risk of hyperkalemia from reninangiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant. 2021;36(5):826-39. doi:10.1093/ndt/gfz263.
147. Komajda M, Anker SD, Cowie MR, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514-22. doi:10.1002/ejhf.510.
148. Beldhuis IE, Lam CSP, Testani JM, et al. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation. 2022; 145(9):693-712. doi:10.1161/CIRCULATIONAHA.121.052792.
149. Pontremoli R, Borghi C, Perrone Filardi P. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):445-52. doi:10.1093/ehjcvp/pvab030.
150. Banerjee D, Rosano G, Herzog CA. Management of heart failure patient with CKD. Clin J Am Soc Nephrol. 2021;16(7):1131-9. doi:10.2215/CJN.14180920.
151. Bhatt DL, Verma S, Braunwald E. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metab. 2019; 30(5):847-9. doi:10.1016/j.cmet.2019.10.008.
152. Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397-407. doi:10.1016/j.jacc.2021.01.044.
153. Pardo-Martínez P, Barge-Caballero E, Bouzas-Mosquera A, et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur J Intern Med. 2022;97:86-94. doi:10.1016/j.ejim.2021.12.027.
154. Жиров И. В., Сафронова Н. В., Терещенко С. Н. Антагонисты минералокортикоидных рецепторов у пациентов с хронической сердечной недостаточностью: мифы и реальность. РМЖ. 2024;6:9-14.
155. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42(5):373-498.